Attention: This page describes uses that are not yet FDA approved.
The Quest Spectrum® has been used in numerous clinical and preclinical trials and has shown potential for a number of promising applications. We are exploring additional uses of the system and would be happy to discuss your interests in future applications.
We consider the use of the Quest Spectrum in combination with Indocyanine Green (ICG) or Methylene Blue in the follow¬ing application to be quite promising:
Sentinel Lymph Node identification using ICG may improve the surgeon’s speed and accuracy in finding the lymphatic channel and nodes. This may result in the surgeon making smaller incisions and speeding up the procedure. All axillary SLNs detected by γ (gamma) tracing are also detected with NIR fluorescence imaging. Clinical trial data suggest Sentinel Lymph Node Detection with ICG provides added value in Breast cancer, Melanoma and Vulvar cancer
SurgiMab and Quest Medical Imaging have entered into a collaboration agreement for the upcoming Phase III clinical trial of Surgimab’s SGM-101 in fluorescent guided colorectal cancer surgery. Click here for more information about this clinical trial.
SurgiMab and Quest Medical Imaging in the news
In this Dutch article and video the research into tumor-specific markers using the Quest Spectrum is showcased. Normally tumor and the tumor-specific markers are invisible to the naked eye. By using the fluorescence imaging technique of the Quest Spectrum the tumor can be made visible. The unique feature of this system is the real-time green colored overlay of the location of the tumor on top of the color image. Hence the title; invisible tumor lights up green.
Quest Medical Imaging and Avelas Biosciences are collaborating on Avelas’ ongoing Phase II/III trial for evaluating the accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant breast tissues.